Page 96 - ITPS-8-1

INNOSC Theranostics and
Pharmacological Sciences Brain glutamate level after treatment with NAC

doi: 10.1097/WNF.0000000000000001 oxidant-antioxidant status. Prog Neuropsychopharmacol Biol
62. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Psychiatry. 2008;32(2):487-491.
Akhondzadeh S. N-acetylcysteine as an adjunctive doi: 10.1016/j.pnpbp.2007.10.002
therapy to risperidone for treatment of irritability in
autism: A randomized, double-blind, placebo-controlled 66. Nascimento MM, Suliman ME, Silva M, et al. Effect of oral
clinical trial of efficacy and safety. Clin Neuropharmacol. N-acetylcysteine treatment on plasma inflammatory and
2015;38(1):11-17. oxidative stress markers in peritoneal dialysis patients:
A placebo-controlled study. Perit Dial Int. 2010;30(3):336-342.
doi: 10.1097/WNF.0000000000000063
doi: 10.3747/pdi.2009.00073
63. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA.
N-Acetylcysteine--a safe antidote for cysteine/glutathione 67. Ooi SL, Green R, Pak SC. N-acetylcysteine for the treatment
deficiency. Curr Opin Pharmacol. 2007;7(4):355-359. of psychiatric disorders: A review of current evidence.
doi: 10.1016/j.coph.2007.04.005 Biomed Res Int. 2018;2018:2469486.
64. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of doi: 10.1155/2018/2469486
N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 68. Van Ameringen M, Patterson B, Simpson W, Turna J.
2013;34(3):167-177. N-acetylcysteine augmentation in treatment resistant
doi: 10.1016/j.tips.2013.01.001 obsessive compulsive disorder: A case series. J Obsessive
Compuls Relat Disord. 2013;2(1):48-52.
65. Selek S, Herken H, Bulut M, et al. Oxidative imbalance in
obsessive compulsive disorder patients: A total evaluation of doi: 10.1016/j.jocrd.2012.10.003

Volume 8 Issue 1 (2025) 90 doi: 10.36922/itps.4887